Key result
This reply discusses the association between final infarct size measured by CMR and long-term outcomes in STEMI patients, presenting no new quantitative data.
Answers are grounded in this paper and cite their sources.
The authors defend the use of admission for heart failure as a valid clinical endpoint in studies assessing the prognostic value of infarct size measured by CMR in STEMI patients.
We welcome the insightful and constructive comments by Dr Benoy N. Shah with regard to our recent paper on the association between final infarct size measured by cardiovascular magnetic resonance (CMR) and long-term outcome in patients with ST-segment elevation myocardial infarction (STEMI).1 Dr Benoy N. Shah questions the use of admission for heart failure as a clinical endpoint, since it may be more prone to bias than reinfarction and mortality. While we agree that admission for heart failure is not quite as straightforward to define as reinfarction and mortality, admission for heart failure may still be considered as a well-defined endpoint, and is used frequently. Also, the two latter …
No takes yet. Share an insight, caveat, or question.
Lønborg et al. (2013) conducted a letter in ST-segment elevation myocardial infarction (STEMI). Final infarct size measured by cardiovascular magnetic resonance (CMR) was evaluated on Long-term outcome (including admission for heart failure, reinfarction, and mortality). This reply discusses the association between final infarct size measured by CMR and long-term outcomes in STEMI patients, presenting no new quantitative data.
Synapse has enriched 10 related papers. Consider them for comparative context: